PEOPLE - Xtent makes appointment:
This article was originally published in Clinica
Drug-eluting stent developer Xtent (Menlo Park, California) has appointed Michael Eagle to its board of directors. Mr Eagle, who has over 30 years experience in the life-sciences industry, was most recently vice-president of manufacturing at Eli Lilly, a post he held for eight years. He is on the board of several companies, including: Favrille (biopharma, chairman); Radiant Medical (endovascular therapeutic cooling); Siegel-Robert (industrial manufacturing); Somaxon Pharmaceutical; and Micrus Endovascular (cerebrovascular implants and disposables).
You may also be interested in...
Study commissioned by the PhRMA underscores concerns about how the coronavirus has disrupted use of physician-administered drugs.
At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.
COVID-driven supply shortages were both the cause of and solution to production deficiencies for manufacturers of neuromuscular blocking agents; US FDA is permitting Mylan, Gland, and Fresenius Kabi to distribute vecuronium bromide and rocuronium bromide even though they do not have the ‘paralyzing agent’ warning on the caps since the products are in high demand at ICUs. The appropriately embossed caps were unavailable due to supply chain disruptions caused by the pandemic.